Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891163 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Depth and Duration of Anesthesia
A Phase 4 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00891163: Completed Phase 4 study, sponsored by ZARS Pharma.
NCT00891163 is a Phase 4 study that has completed, run by ZARS Pharma. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00891163, a Phase 4 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the depth (mm) of anesthesia provided by the Synera topical patch (using sensory depth and pain depth evaluations), and to determine the duration (minutes) of anesthesia provided by the Synera topical patch (using dermal sensory testing and thermal sensory testing evaluations), compared with a matching heated placebo patch.
Interventions
- DRUG Placebo Patch
- DRUG Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
What the finished NCT00891163 record still lists
NCT00891163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Patch is the first listed.
NCT00891163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00891163 about?
NCT00891163 is a clinical study titled "Evaluate the Depth and Duration of Anesthesia". The purpose of the study is to determine the depth (mm) of anesthesia provided by the Synera topical patch (using sensory depth and pain depth evaluations), and to determine the duration (minutes) of anesthesia provided by the Synera topical patch (using dermal sensory testing and thermal sensory te...
What is the current status of trial NCT00891163?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2006-12. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00891163?
The interventions under investigation include: Placebo Patch (DRUG), Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine) (DRUG).
Who is sponsoring clinical trial NCT00891163?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00891163's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia